AUM Biosciences enters in a Strategic Collaboration with Handok and CMG Pharm to develop ‘CHC2014’, New Pan-TRK Inhibitor for Cancer Treatment

AUM will receive worldwide rights excluding Korea in all indications Handok, CMG (combined market cap of >1 Trillion KRW) will execute a stock purchase program with AUM Biosciences CHC2014 is a highly selective TRK kinase inhibitor with excel...

Full "IntellAsia: Resources" article